Understanding how ZMYM2 influences gene regulation in leukemia
Official title: Towards a structural understanding of transcriptional regulation by ZMYM2-KDM1A-CoREST
Funded at Dana-Farber Cancer Inst · NIH-11055048 · Data updated 2026-11-12
This study is looking at how a protein called ZMYM2 affects gene activity in acute myeloid leukemia (AML), with the hope of finding new ways to treat this type of cancer by understanding how it works with other proteins.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | December 18, 2024 |
| Project end | November 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $125,000 |
| NIH project number | 1K99GM154065-01A1 |
| Project ID | NIH-11055048 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with acute myeloid leukemia, particularly those who may benefit from new therapeutic approaches.
✕Less likely to help
Patients with other types of leukemia or those not diagnosed with any hematologic malignancies may not receive direct benefits from this research.
What this research studies
This research investigates the role of the ZMYM2 protein in regulating gene expression, particularly in the context of acute myeloid leukemia (AML). By studying how ZMYM2 interacts with other proteins in the KDM1A-CoREST complex, the research aims to uncover the mechanisms behind transcriptional repression. This could lead to new therapeutic strategies for treating AML by targeting these molecular interactions. The research combines biochemical techniques with structural biology to provide a detailed understanding of these processes.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments for acute myeloid leukemia by targeting the mechanisms of gene regulation.
How similar studies have gone: Previous research has shown promising results in targeting epigenetic regulators for leukemia treatment, suggesting that this approach could be effective.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Wachter, Franziska — Dana-Farber Cancer Inst
- Study coordinator: Wachter, Franziska
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.